The therapeutic landscape for cells engineered with chimeric antigen receptors. Academic Article uri icon

Overview

abstract

  • Despite the global rapid increase in the number of clinical trials employing chimeric antigen receptors (CARs), no comprehensive survey of their scope, targets and design exists. In this study, we present an interactive CAR clinical trial database, spanning 64 targets deployed in T cells (CAR-T), natural killer cells (CAR-NK) or mixtures (CAR-NK/T) from over 500 clinical trials in 20 countries, encompassing >20,000 patients. By combining these data with transcriptional and proteomic data, we create a 'targetable landscape' for CAR cell therapies based on 13,206 proteins and RNAs across 78 tissues, 124 cell types and 20 cancer types. These data suggest a landscape of over 100 single targets and over 100,000 target pairs using logical switches for CAR cell engineering. Our analysis of the CAR cellular therapeutic landscape may aid the design of future therapies, improve target-to-patient matching, and ultimately help inform our understanding of CAR therapy's safety and efficacy.

publication date

  • January 6, 2020

Research

keywords

  • Cell Engineering
  • Receptors, Chimeric Antigen

Identity

Scopus Document Identifier

  • 85077601962

Digital Object Identifier (DOI)

  • 10.1080/2162402X.2017.1368604

PubMed ID

  • 31907405

Additional Document Info

volume

  • 38

issue

  • 2